A pathologically elevated interstitial fluid pressure (IFP) is a characteristic of both clinical and experimental carcinoma. The soluble TGF-b receptor type II-murine Fc:IgG 2A chimeric protein (Fc:TbRII) lowers IFP in the KAT-4 experimental model for anaplastic thyroid carcinoma. Analyses of messenger RNA (mRNA) expressions by Affymetrix microarrays and RNase protection assays, as well as of protein expressions identified tumor macrophages as targets for Fc:TbRII. Treatment with Fc:TbRII reduced albumin extravasation, increased coverage of a-smooth muscle actin-positive cells and reduced expression of NG2, a marker of activated pericytes, in KAT-4 carcinoma blood vessels. Specific inhibition of interleukin-1 (IL-1), a major cytokine produced by activated macrophages, lowered carcinoma IFP to a similar degree as Fc:TbRII but had no significant effect on the parameters of blood vessel maturation. Neither Fc:TbRII nor inhibition of IL-1 changed blood vessel density. Finally, pretreatment of KAT-4 carcinomas with Fc:TbRII increased the antitumor efficacy of doxorubicin. Our data emphasize a potential role of tumor macrophages in carcinoma physiology and identify these cells as potential stromal targets for treatment aimed to improve efficacy of chemotherapy.
Resistance of tumors to chemotherapy can in part be explained by impaired delivery of chemotherapeutic agents into the tumor tissue. 1 The pathologically elevated interstitial fluid pressure (IFP), a characteristic of solid malignancies, reflects a barrier for drug transport into tumors. [2] [3] [4] [5] [6] [7] An increased IFP reduces the transcapillary pressure gradient driving outward fluid flux over the capillary wall. 8 Rapid and transient lowering of IFP in experimental carcinoma increases convective transport of low molecular mass compounds into the carcinoma tissue, as well as efficacy of chemotherapy during the time period of lowered tumor IFP. [5] [6] [7] Long-term treatment with inhibitors of the platelet-derived growth factor (PDGF), 9 vascular endothelial growth factor (VEGF) 10 systems or with dexamethasone 11 lowers tumor IFP in several experimental carcinoma models. Lowering of tumor IFP by inhibition of PDGF parallels an increased uptake of and sensitivity to cytostatic drugs. 12, 13 Furthermore, lowering of tumor IFP by treatment with a specific inhibitor of VEGF paralleled the increased efficacy of conventional chemotherapy for human rectal carcinoma. 14 Thus, available data suggest that enhancement of drug delivery to solid malignancies by reduction of tumor IFP constitutes an attractive modality to augment efficacy of conventional chemotherapy. The pathogenic mechanisms involved in the generation of the high tumor IFP are not fully known although several mechanisms have been suggested (for a recent review, see Heldin et al 15 ) . TGF-b is believed to play a dual role during the progression of carcinoma towards a malignant metastatic phenotype; 16 during early stages, negatively controlling carcinoma cell proliferation and at later stages promoting metastases. Long-term presence of Fc:TbRII suppresses metastasis formation in experimental tumor models. 17, 18 Treatment of xenograft human KAT-4 anaplastic thyroid carcinoma in mice with a soluble TGF-b receptor type IImurine Fc:IgG 2A chimeric protein (Fc:TbRII) lowered tumor IFP in a dose-and time-dependent manner. 19 The present study was initiated to delineate potential mechanisms by which Fc:TbRII reduced KAT-4 carcinoma IFP. KAT-4 carcinomas were chosen since they are well characterized and cultured KAT-4 carcinoma cells are refractory to TGF-b. 19 
Materials and methods

Reagents
The TGF-b receptor type II-murine Fc:IgG 2A chimeric protein (Fc:TbRII) has been described previously. 20 Human interleukin-1 receptor antagonist (rh-IL-1 Ra; Kineret) was from Amgen (Louisville, KY, USA). Anti-mouse CD31/PECAM-1 monoclonal antibody (Mab), biotin anti-mouse panendothelial cell antigen Mab, anti-mouse Ly-6G and Ly-6C (Gr-1) (RB6-8C5) Mab and FITC-conjugated anti-mouse I-A/I-E (2G9) Mab were from BD PharMingen (San Diego, CA, USA). Rat anti-mouse F4/80 Mab was from Serotec (Oxford, UK). Goat anti-actin (I-19) IgG was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal anti-laminin IgG and FITC-conjugated mouse anti-a smooth muscle actin (aSMA) Mab (clone 1A4) were from Sigma (St Louis, MO, USA), rabbit polyclonal anti-NG2 IgG was from Chemicon (Temecula, CA, USA), Alexa Flour 488 goat anti-rabbit IgG (H þ L) and Alexa Fluor 594 goat anti-rat IgG (H þ L) were from Molecular Probes (Eugene, OR, USA). Tumor cells were visualized with rabbit anti-TPA:B1 IgG (Sangtec Medical AB, Bromma, Sweden). Anti-mouse LYVE-1 IgG detecting lymphatic vessel endothelial HA-receptor-1 and anti-mouse VEGFR-3 (AFL-4) Mab were kindly supplied by Dr Kari Alitalo (University of Helsinki, Finland). Human and murine VEGF ELISA kits were from R&D Systems (Abingdon, Oxon, UK).
Tumors and Treatments
KAT-4 anaplastic thyroid carcinoma cells 21 were injected subcutaneously (s.c.) in the left flank of athymic C57 bl/6 mice as described. 19 Tumor IFP was measured by the 'wick-in-the needle' technique as described. 5 All animal experiments were approved by the Ethical Committee for Animal Experiments in Uppsala (Sweden). The number of animals was minimized to comply with guidelines from the Ethical Committee.
Affymetrix Microarrays
Total RNA was extracted from KAT-4 carcinomas using a LiCl/Urea-method. 23 Preparation of labeled cRNA probe was performed according to recommendations from Affymetrix Inc. Poly(A) messenger RNA (mRNA) was isolated and used as template for double-stranded cDNA synthesis with an oligo(dT)24 primer containing a T7 RNA polymerase promoter site added to the 3 0 end. The cDNA was extracted with phenol-chloroform, ethanol-precipitated, and used as a template for in vitro transcription with biotin-labeled nucleotides. Labeled cRNA was fragmented and a hybridization mix was generated. Aliquots of each sample (10 mg cRNA in 200 ml hybridization mix) were hybridized to a Gene-chip Mu74Av2 array. Scanned files in the 'Cel' format from arrays lacking significant artifacts were exported to the Rosetta Resolver software suite. Intensity ANOVA analysis was performed to reveal transcripts with differences in expression between treated with Fc:TbRII or IgG 2A groups with Pr0.05.
Morphological Analyses
Immunohistochemistry and double immunofluorescence stainings of cryosections were performed as previously described. 24, 25 The density of macrophages and granulocytes was determined using a counting grid (15-34 vision fields, Â 500).
Results are expressed as cell density per mm 2 of the tumor viable zone and as a percent of total cellular density. Analyses by confocal microscopy were made with a Leica TCS SP spectral confocal microscope (Leica Microsystems Heidelberg GmbH).
In Vivo Perfusion and Permeability Assay
After treatment with Fc:TbRII, IgG 2A or rh-IL-1 Ra perfused tumor vessels were visualized using FITCDextran (mean molecular mass 2000 kDa; Sigma). Vascular permeability was assessed by determining Evans blue dye (EBD) leakage into the tumor interstitium. EBD (Sigma, 30 mg/kg) was administered i.v. 30 min and FITC-Dextran (100 mg/kg) 2 min before killing an animal. To evaluate perfused area of tumor vasculature and leakage of EBD, either 50 mm formalin-fixed tissue sections were analyzed by confocal microscopy or 20 mm frozen sections by fluorescent microscopy. Vascular leakage was quantified based on the amount and distribution of extravasated EBD and was graded from 0 to þ þ þ. Data were dichotomized into two groups: one low leakage group (0 and þ ) and one high leakage ( þ þ and þ þ þ ). Data are presented as percentage of vessels with high leakage for EBD in 12 fields of vision from six sections per tumor taken 100 mm apart and assessed under low magnification. The extent of EBD leakage was analyzed by densitometry using the NIH Image 1.62 software. Digital images were analyzed in a gray-scale mode and dye density in tumor sections presented as number of pixels per area of tumor tissue.
Immunoblot Analysis
Viable parts of KAT-4 tumors were dissected out and lysed as previously described. 19 The pellet (25 000 g) of insoluble cellular components from the lysis was subjected to sonication in 50 mM Tris HCl pH 7.4, 5 mM EDTA and 1% sodium dodecylsulfate. Immunoblot analyses were performed as previously described, 19 on both cell fractions using the anti-NG2 or anti-aSMA antibodies. The second solubilization appeared to contain approximately 70-80% of the specific signal in the NG2 immunoblots.
RNase Protection Assay
Total RNA was extracted from tumor tissues as described above. RNase protection assay (RPA) was performed using BD RiboQuant Multi-Probe RPA System kits (mCK-2b, mAngio-1 and hAngio-1) (BD Biosciences). The mRNA expression levels were measured using a Phosphor Imager (Fuji 2000, Fuji, Tokyo, Japan). The levels were normalized to L32 (mouse) or GAPDH (human) housekeeping genes and presented as relative mRNA expression.
Determination of VEGF Protein Level in KAT-4 Tumors
Specimens from the viable zone of KAT-4 tumors were extracted (1:10 w/v) in 50 mM Tris-HCl pH 7.5, 5 mM EDTA, 1 M NaCl, 1% NP-40, 0.26% Nadeoxycholate, 50 mM NaF, 50 mM b-glycerophosphate and protease inhibitors, homogenized by freeze-thawing and cleared by centrifugation at 17 000 g for 20 min. A volume of 1 M NaCl was used to extract VEGF bound to heparan sulfate proteoglycans in the extracellular matrix (ECM) or cell surfaces. Supernatants were diluted five times with 10 mM Tris-HCl prior to measurements. Total protein concentration in the specimens was determined using the bicinchoninic acid protein assay (BCA, Pierce, Rockford, IL, USA) and VEGF determined using a commercial ELISA kit (R&D Systems).
Statistical Methods
The unpaired, two-tailed Student's t-test and the Mann-Whitney U-test were used. Po0.05 was considered statistically significant. Standard deviations of data points are indicated in the figures.
Results
Fc:TbRII Downregulates Genes Expressed by Macrophages
Available data suggest that treatment with Fc:TbRII modifies host rather than carcinoma cell activity in KAT-4 tumors. 19 Expression of mouse (host) genes was investigated by mouse Affymetrix microarray analyses. Differences in gene expressions in carcinomas from animals treated with Fc:TbRII (n ¼ 3) or IgG 2A (n ¼ 3) were compared. A set of 281 genes out of the totally B1.25 x 10 4 genes presented on the chips were significantly changed (Po0.05; ANOVA). Of these genes, 41 were either upregulated by Z100% or downregulated by Z50% (Table 1) .
Several genes known to be expressed by macrophages were significantly downregulated after treatment with Fc:TbRII (Table 1) . These genes included S100 calcium-binding protein A9, major histocompatibility complex (MHC) class II antigens, mannose receptors, IL-1b and monocyte chemotactic protein-2 (MCP-2). Most of the highly expressed genes encoding ECM proteins were not regulated in KAT-4 carcinomas subjected to TGF-b1 and -b3 inhibition, for example, genes encoding interstitial collagens (data not shown). The only ECM protein that was significantly downregulated was the small leucinerich repeat proteoglycan, fibromodulin. Genes encoding the hemoglobin A-and B-chains were most markedly upregulated. The significance of the latter finding is unclear.
RPA and immunofluorescence stainings were performed to validate the microarray results. RPA of several mouse cytokine genes revealed a specific downregulation of IL-1b and IL-1Ra (Figure 1a) . The IL-1Ra gene was not included in the microarrays. In agreement with the microarray data, quantitative morphological analyses showed that the number of macrophages was reduced by around 30% in tumors treated with Fc:TbRII (n ¼ 5) compared to control tumors treated with IgG 2A (n ¼ 5; Po0.0026) ( Figure  1b) . The microarray analyses showed a particularly strong downregulation of mRNAs encoding MHC class II antigens ( Table 1) Affymetrix microarrays encompassing B1.25 Â 10 4 mouse genes were hybridized with mRNA from KAT-4 carcinomas treated with Fc:TbRII (n ¼ 3) or with IgG 2A (n ¼ 3). A set of 41 genes that fulfilled the following two criteria are listed: significant up-or downregulation between the two groups (Po0.05; ANOVA); and upregulation by Z100% or downregulation by Z50%.
tumors treated with Fc:TbRII. Granulocytes comprised around 1% of the cell mass in KAT-4 carcinomas and their number was not changed after inhibition of TGF-b1 and -b3 (data not shown).
Inhibition of TGF-b1 and -b3 Modifies Vascular Morphology
The effects of Fc:TbRII on IFP in KAT-4 carcinomas may be due to changes in vascular function. This is based on the finding that inhibitors of the VEGF system lower tumor IFP and 'normalize' vascular function in carcinoma. 14, 26 We therefore investigated potential effects of vessel maturation after treatment of KAT-4 carcinoma with Fc:TbRII. Expression of NG2 protein was downregulated (Figure 2a) , whereas aSMA expression was either unaffected or slightly upregulated (Figure 2a) . The percentage of CD31-positive vessels that were also positive for aSMA was significantly increased in tumors treated with Fc:TbRII (Figure 2b, c) . In addition, more aSMA-expressing extravascular cells were present in tumors treated with Fc:TbRII than with IgG 2A (arrows in Figure 2b ). To investigate blood perfusion in KAT-4 carcinomas, tumor-bearing mice were injected with high molecular mass FITC-labeled dextran prior to killing. There was no significant difference between the number or distribution of perfused vessels (Figure 2f ) in tumors treated with Fc:TbRII (65724 vessels per mm 2 , n ¼ 5) and IgG 2A controls (65712 vessels per mm 2 , n ¼ 4). Vessel integrity was investigated by semiquantitative analyses of the leakage of EBD. 27 In the circulation, EBD is irreversibly bound to albumin. EBD present in tissues, therefore, reflects albumin leakage from capillaries. 28 Treatment of mice bearing KAT-4 carcinomas with Fc:TbRII reduced EBD leakage in the carcinomas compared to IgG 2A treatment ( Figure  2f ). The significance of this difference was assessed by a grading procedure (Figure 2d ) or by densitometric analysis (Figure 2e ).
Together these data suggest that Fc:TbRII normalized blood vessels with regard to pericyte activation, a-SMA coverage and extravasation of albumin.
Inhibition of IL-1 Reduces Tumor IFP
The gene expression data, as well as immunohistochemical analyses, suggested that interference with TGF-b1 and/or -b3 modulated macrophages in KAT-4 carcinomas. Since IL-1b was reduced after treatment with Fc:TbRII and since it is secreted by activated macrophages, its potential role in maintaining a high IFP in KAT-4 carcinoma was investigated. Treatment of mice carrying KAT-4 carcinomas with rh-IL-1 Ra (n ¼ 9) significantly reduced IFP to a similar degree as treatment with Fc:TbRII (n ¼ 15; Po0.05) (Figure 3 and data from Lammerts et al 19 ) . Combined treatment of animals with Fc:TbRII and rh-IL-1 Ra (n ¼ 7) had no additive effect on IFP compared to any of the inhibitors alone ( Figure 3) .
The number of infiltrating macrophages was reduced by 43% to 453754 cells per mm 2 (9.571.3% of total cellular density) after treatment with rh-IL-1 Ra (n ¼ 4) (cf Figure 1b) . Furthermore, the fraction of MHC class II antigens expressing F4/ 80-positive macrophages was reduced by 28% in rh-IL-1 Ra-treated carcinomas compared to controls.
Inhibition of IL-1 had No Effect on Vascular Morphology
Whereas expression of NG2 protein was downregulated in KAT-4 carcinomas treated with Fc:TbRII, treatment with rh-IL-1 Ra did not decrease this expression (data not shown). Qualitative immunofluorescence analyses revealed no significant change in perivascular aSMA-expressing cells in KAT-4 carcinomas treated with rh-IL-1 Ra compared to controls (data not shown). Furthermore, no significant change in the percentage of CD31 positive vessels that were also positive for aSMA was observed after treatment with rh-IL-1 Ra ( Figure  4a ). However, there was a trend for a decreased extravasation of albumin after treatment with rh-IL-1 Ra although this effect did not reach significance (Figures 4b and c) .
Inhibition of TGF-b1 and -b3 or IL-1 did not Influence Angiogenesis
The microarray analyses of KAT-4 tumors showed no changes in expression of genes associated with vascular function. Furthermore, expressions of several mouse mRNAs encoding various markers of angiogenesis were similar in KAT-4 carcinomas from animals treated either with IgG 2A , Fc:TbRII or rh-IL-1 Ra (Figure 5a) . Notably, the expression of human VEGF mRNA was similar in the different groups of carcinomas (Figure 5b ). Production of VEGF by cultured KAT-4 cells was B0.2 ng/h/10 6 cells and this production was not affected by the addition of Fc:TbRII or rh-IL-1 Ra to the culture media (data not shown). Furthermore, levels of VEGF relative to total protein in extracts from KAT-4 carcinomas treated with Fc:TbRII or rh-IL-1 Ra were not different from the respective controls (data not shown).
Microvessel density and distribution within the viable zone was similar in carcinomas treated with Fc:TbRII (n ¼ 4), rh-IL-1 Ra (n ¼ 6) or IgG 2A (n ¼ 4) when assessed by morphometry of CD31 positive structures (Figure 5c ). Similar results were obtained when vessels were visualized by staining for the 'panendothelial cell antigen' (data not shown). Laminin was expressed in vascular basement membranes and this expression was not qualitatively affected by either of the two inhibitors (data not shown). Expression of VEGFR-3 and lymphatic vessel endothelial HA-receptor-1 were not detectable in the viable zone of tumors treated with Fc:TbRII, rh-IL-1 Ra or IgG 2A (data not shown).
Inhibition of TGF-b1 and -b3 Augments Efficacy of Doxorubicin
The potential of treatment with Fc:TbRII to augment chemotherapy was investigated. Animals with KAT-4 carcinomas were pretreated with 1 mg/kg of Fc:TbRII (n ¼ 4), or IgG 2A (n ¼ 4). Starting 10 days after the administration of Fc:TbRII animals were treated for 2 weeks with doxorubicin in a dose pretitrated to have minimal effects on tumor growth. Control animals received a single injection of Fc:TbRII alone at a dose of 1 mg/kg (n ¼ 4). The dose of 1 mg/kg of Fc:TbRII was chosen since it was the lowest dose of Fc:TbRII which reduced IFP in KAT-4 carcinoma. 19 The antitumor effect of doxorubicin was significantly greater after pretreatment with Fc:TbRII compared to IgG 2A (Figure 6a ). In contrast, the growth inhibitory effect of doxorubicin on cultured KAT-4 cells was not influenced by the presence of either TGF-b1 or Fc:TbRII (Figure 6b ). carcinomas. Administration of rh-IL-1 Ra twice daily for 10 days with 7.5 mg/injection to KAT-4 carcinoma-bearing mice lowered tumor IFP by around 50%, that is, to the similar degree as Fc:TbRII alone. 19 There was no additive effect on tumor IFP observed after combined treatment with Fc:TbRII (a single injection at a dose of 10 mg/kg) and rh-IL-1 Ra. 
Discussion
The present data suggest that carcinoma-associated macrophages are involved in the regulation of IFP in experimental carcinoma. First, analyses of global gene expression patterns in KAT-4 carcinoma revealed that genes expressed by macrophages constituted a major group of genes that were downregulated after interference with TGF-b1 and -b3. Genes encoding MHC class II antigens, mannose receptors, IL-1b, S100 calcium-binding protein A9 (MRP-14) and the chemokine MCP-2 were downregulated. Since MHC class II antigens expression could only be positively identified in F4/80-positive macrophages, the downregulation of MHC class II antigens strongly suggests that macrophages are targeted by Fc:TbRII. Second, the number of intratumoral macrophages decreased after administration of Fc:TbRII, an effect coinciding with the lowering of tumor IFP. The reduction in macrophage numbers after treatment with the TGF-b inhibitor is in line with the well-established function of TGF-b1 as a chemoattractant for monocytes. 29, 30 Third, the specific IL-1 inhibitor, rh-IL-1 Ra reduced IFP in KAT-4 carcinoma. Macrophages are major producers of secreted IL-1b in reactive tissues 31 and cultured KAT-4 cells secreted neither IL-1a nor -1b (data not shown). The expression of mouse IL-1a mRNA was low in KAT-4 carcinomas, suggesting that the effects of rh-IL-1 Ra on tumor IFP were due to inhibition of IL-1b. TGF-b induces IL-1b mRNA expression by cultured human monocytes, 29 a finding in line with the present result that inhibition of TGF-b1 and -b3 reduced IL-1b mRNA in KAT-4 carcinomas. In addition, treatment with the anti-inflammatory drug dexamethasone reduced macrophage density, expression of MHC class II antigens by macrophages and lowered IFP in KAT-4 carcinoma (data not shown). It is noteworthy that inhibitors of several growth factors or cytokines that are produced by activated macrophages, such as PDGF, 9 TGF-b1 andb3, 19 IL-1 (present study) and VEGF 10 lower IFP in experimental carcinoma.
Expression of MHC class II antigens and mannose receptors by macrophages serve as markers of activation of these cells. 32 Fc:TbRII markedly downregulated class II expression by macrophages in KAT-4 carcinomas demonstrating that this inhibitor deactivated or, alternatively inhibited the activation of intratumoral macrophages. Both rh-IL-1 Ra and Fc:TbRII reduced the number of macrophages by B30-40% in KAT-4 carcinoma tissue, but no linear correlation between macrophage numbers and KAT-4 carcinoma IFP could be established (data not shown). Based on these notions, it therefore seems plausible that macrophage activation rather than number is important for their putative effects on tumor IFP.
Microvessel density in KAT-4 carcinomas was not affected by treatment with either Fc:TbRII or rh-IL-1 Ra. These findings show that the lowering of tumor IFP was not due to antiangiogenic effects of these inhibitors. However, treatment with Fc:TbRII significantly decreased extravasation of albumin in the carcinomas. A reduced protein leakage presumably reflects a normalization or maturation of the carcinoma vasculature. The decrease in NG2 expression, a marker of activated pericytes, 24, 33, 34 thus likely reflected a change in pericyte phenotype towards one more resembling that prevalent in normal and mature microvessels. The higher percentage of CD31 positive vessels containing aSMA-positive cells also favors the notion of a maturation of blood vessels in KAT-4 carcinomas from mice treated with Fc:TbRII. These findings speak in favor of a mechanism for IFP lowering by Fc:TbRII involving maturation of tumor blood vessels in KAT-4 carcinoma. Inhibition of IL-1 reduced IFP to a similar degree as Fc:TbRII but had less pronounced or no effects on the parameters for blood vessel maturation that were investigated. Furthermore, inhibition of IL-1 reduced albumin extravasation albeit this effect was not statistically significant. It is thus possible that Fc:TbRII and rh-IL-1 Ra lower tumor IFP by different mechanisms. Alternatively, the two inhibitors lowered IFP in KAT-4 carcinoma by a common mechanism involving subtle changes in blood vessel maturation. The finding that rh-IL-1 Ra reduced IFP in a nonadditive manner to Fc:TbRII is compatible with a common mechanism for lowering of carcinoma IFP by Fc:TbRII and rh-IL-1 Ra.
VEGF potently stimulates protein leakage from blood vessels 35 and activates nonendothelial vascular cells, for example, NG2 expression by pericytes in in vivo models of VEGF driven vasculogenesis. 36 The proangiogenic activity of IL-1a has been ascribed to a stimulation of VEGF production by inflammatory cells. 37 Furthermore, treatment with inhibitors of the VEGF system reduces IFP, microvessel density and plasma protein leakage in experimental, 26 as well as human rectal carcinoma. 14 An attractive model is therefore that the effects of Fc:TbRII and rh-IL-1 Ra at least in part were due to a reduction of VEGF activity in KAT-4 carcinoma. The present findings do, however, not favor such a model. First and most importantly, neither Fc:TbRII nor rh-IL-1 Ra reduced microvessel density in KAT-4 carcinoma. This would be expected if inhibition of the VEGF system constituted a common mechanism for the IFP lowering by the two inhibitors. Second, levels of human and mouse VEGF mRNAs and protein were not changed in KAT-4 carcinomas treated with any of the two inhibitors. Third, VEGF production by cultured KAT-4 cells was not changed by the presence of Fc:TbRII or rh-IL-1 Ra (data not shown). Based on these findings it seems less likely that modulations of VEGF levels constituted a common mechanism for IFP lowering by Fc:TbRII or rh-IL-1 Ra. Long-term presence of Fc:TbRII suppresses metastasis formation in experimental tumor models. 17, 18 The present data showing that Fc:TbRII increases efficacy of chemotherapy should add to the clinical potential for adjuvant treatment of advanced malignancies using specific Fc:TbRII.
In conclusion, we present evidence suggesting that macrophages play a role in the generation of the pathologically elevated tumor IFP in a model for experimental carcinoma. Furthermore, our data propose that TGF-b1 and/or -b3 modulate macrophages in carcinoma.
